XML 37 R24.htm IDEA: XBRL DOCUMENT v3.24.3
Net Product Sales (Tables)
 9 Months Ended
Sep. 30, 2024
Revenue from Contract with Customer [Abstract]  
Schedule of Revenue from External Customers by Geographic Areas
Net product sales by customer geographic location were as follows (in millions):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
United States$1,215 $913 $1,477 $916 
Europe281 103 281 739 
Rest of world324 741 413 2,223 
Total $1,820 $1,757 $2,171 $3,878 
Schedule of Disaggregation of Revenue
Net product sales by product were as follows (in millions):

Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
COVID-19
$1,810 $1,757 $2,161 $3,878 
RSV
10 — 10 — 
Total $1,820 $1,757 $2,171 $3,878 
The following table summarizes product sales provision for the periods presented (in millions):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Gross product sales $2,964 $2,420 $3,377 $4,541 
Product sales provision:
Wholesaler chargebacks, discounts and fees
(1,053)(479)(1,053)(479)
Returns, rebates and other fees
(91)(184)(153)(184)
Total product sales provision(1)
$(1,144)$(663)$(1,206)$(663)
Net product sales $1,820 $1,757 $2,171 $3,878 
_______
(1)Includes an adjustment of approximately $140 million in the third quarter of 2024, reflecting a reduction in prior period provision estimates, primarily related to returns for the previous COVID-19 vaccine season that closed during the quarter.
The following table summarizes other revenue for the periods presented (in millions):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Grant revenue$7 $44 $27 $96 
Collaboration revenue28 30 35 63 
Licensing and royalty revenue
7 — 37 — 
Total other revenue$42 $74 $99 $159 
Schedule of Changes in Balances of Receivables and Contract Liabilities
The following table summarizes the activities related to product sales provision recorded as accrued liabilities for the nine months ended September 30, 2024 (in millions):
Returns and other fees
Balance at December 31, 2023$(556)
Provision related to sales made in 2024
(308)
Provision related to sales made in prior periods(1)
155 
Payments and returns related to sales made in current period 42 
Payments and returns related to sales made in prior year
264 
Balance at September 30, 2024$(403)
_______
(1)Primarily reflecting a reduction in prior period return estimates for the previous COVID-19 vaccine season that closed during the quarter.
The following table summarizes the activities in deferred revenue for the nine months ended September 30, 2024 (in millions):
December 31, 2023AdditionsDeductionsSeptember 30, 2024
Product sales$613 $224 $(394)$443 
Grant revenue4 8 (1)11 
Collaboration revenue34 7 (34)7 
Licensing and royalty revenue
— 20 (7)13 
Total deferred revenue$651 $259 $(436)$474